Boost Biopharma, Inc.

Boost Biopharma’s innovative Rapid Antigen Deployment (RAD) Process enables the rapid generation of protein subunit vaccine antigens and monoclonal antibodies. The company has developed vaccines for a wide range of pathogens of global importance, including SARS-CoV-2, Dengue virus, Zika virus, West Nile virus, and Japanese Encephalitis, with other vaccines and antibodies in development. Boost is collaborating with biopharmaceutical firms globally, including companies with existing approved and marketed vaccines. We offer single vaccine licenses, access to our inventory of antigens for commercial development, and prioritized access.